Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil

Genetics and Molecular Biology

Volumn 35, Issue 3, 2012, Pages 599-602

  Dillenburg, Crisle Vignol ^a   Bandeira, Isabel Cristina ^a   Tubino, Taiana Valente ^a   Rossato, Luciana Grazziotin ^a   Dias, Eleonora Souza ^b   Bittelbrunn, Ana Cristina ^a   Leistner Segal, Sandra ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b Hospital Materno Infantil Presidente Vargas   (Brazil)

Author keywords

Ashkenazi Jews; BRCA1; BRCA2; Breast cancer; Mutation

Indexed keywords

ARTICLE; BRAZIL; FAMILY HISTORY; FEMALE; GENE DELETION; GENE INSERTION; GENETIC DRIFT; HETEROZYGOTE; HUMAN; JEW; MEDICAL HISTORY; NEOPLASM; ONCOGENE; POPULATION DISPERSION; PREVALENCE; TUMOR SUPPRESSOR GENE;

EID: 84865362254     PISSN: 14154757     EISSN: 16784685     Source Type: Journal    
DOI: 10.1590/S1415-47572012000400009     Document Type: Article

References (25)

1. Abeliovich D, Kaduri L, Lerer I, Weinberg N, Gail A, Sagi M, Zlotogora J, Heching N and Peretz T (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60:505-514.
2. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130.
3. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E and Sadetzki S (2008) Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer. J Clin Oncol 26:20-25.
4. Claus EB, Risch N and ThompsonWD(1991) Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48:232-242.
5. Claus EB, Schildkraut J, Iversen ES, Berry D and Parmigiani G (1998) Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst 90:1824-1829.
6. Easton DF, Ford D and Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56:265-271.
7. Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST and Eng CM (1998) Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 63:45-51.
8. Gershoni-Baruch R, Dagan E, Fried G, Kepten I and Robinson E (1999) BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. Eur J Hum Genet 7:833-836.
9. Goodman RM (1979) Genetic Disorders Among the Jewish People. 1st edition. Johns Hopkins University Press, Baltimore, 512 pp.
10. Hodgson SV, Heap E, Cameron J, Ellis D, Mathew CG, Eeles RA, Solomon E and Lewis CM (1999) Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. J Med Genet 36:369-373.
11. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N et al. (2004) The breast cancer family registry: An infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6:375-389.
12. Kadouri L, Temper M, Grenader T, Abeliovich D, Hamburger T, Peretz T and Lotem M (2009) Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin. Fam Cancer 8:29-32.
13. King MC, Marks JH and Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646.
14. Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Palmer C, Rapaport H, Nafa K, Ellis NA and Offit K (2004) Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst 96:68-70.
15. Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, Shohat M, Weber BL, Beller U, Lahad A et al. (1997) Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: Frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 60:1059-1067.
16. Miller SA, Dykes DD and Polesky HF (1988) A simple salting out procedure for extracting DNA from nucleated cell. Nucleic Acids Res 16:1215.
17. Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J and Russo D et al. (2000) BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. AmJ Hum Genet 66:1259-1272.
18. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop T, Kelsell D et al. (1996) Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: Results of an international study. Am J Hum Genet 58:271-280.
19. Offit K, Gilweski T, McGuire P, Schluger A, Hampel H, Brown K, Swensen J, Neuhausen S, Skolnick M, Norton L et al. (1996) Germline BRCA1 185delAG mutation in Jewish women with breast cancer. Lancet 347:1639-1943.
20. Risch N, Tang H, Katzenstein H and Ekstein J (2003) Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection. Am J Hum Genet 72:812-822.
21. Roa BB, Boyd AA and Richards CS (1996) Ashkenazi jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14:185-187.
22. Rohlfs EM, Learning WG, Friedman KJ, Couch FJ, Weber BL and Silverman LM (1997) Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chemistry 43:24-29.
23. Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J, Dann JL and King MC (1997) BRCA2 in American families with four or more cases of breast or ovarian cancer: Recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 60:1031-1040.
24. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC and Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408.
25. Warner E, Goodwin P, Foulkes W, Meschino W, Goss P, Ozcelik H, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V et al. (1999) Prevalence and penetrance of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91:1241-1247.